US approves UCB’s Cimzia for psoriasis

29th May 2018 Uncategorised 0

Drug is the first Fc-free, PEGylated anti-TNF treatment option for this indication and marks UCB’s entry into immuno-dermatology

More: US approves UCB’s Cimzia for psoriasis
Source: News